Posted on27 January 2012. Tags: Advanced Cancer, Advanced Renal Cell Carcinoma, Axitinib, Cancer Patients, carcinoma, Drugs, Fda, Fda Approved, Fda Food, Food And Drug, Food And Drug Administration, Kidney Cancer, Pfizer, Pfizer Inc, Pharmaceutical Giant Pfizer, Renal Carcinoma, Renal Cell Carcinoma
The US FDA has approved Inlyta (axitinib) for the treatment of advanced renal cell carcinoma, a type of kidney cancer, in patients with whom other drugs have not been effective, the FDA (Food and Drug Administration) announced today. Inlyta is made and marketed by pharmaceutical giant Pfizer Inc...
Read original story